Mendiola-Pastrana IR, López-Ortiz G

Language: Spanish
References: 17
Page: 63-64
PDF size: 99.16 Kb.

Text Extraction

No abstract.

REFERENCES

1. Stirrup O, Boshier F, Venturini C, Guerra-Assunção JA, Alcolea-Medina A, Beckett A, et al. SARSCoV- 2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study. BMJ Open Respir Res. 2021;8(1):e001029.

2. Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum Genomics. 2020;14(1):40.

3. Patone M, Thomas K, Hatch R, Tan PS, Coupland C, Liao W, et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis. 2021;21(11):1518-1528.

4. Lin L, Liu Y, Tang X, He D. The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern. Front Public Health. 2021;9:775224.

5. Mendiola-Pastrana IR, López-Ortiz E, Río de la Loza-Zamora JG, González J, Gómez-García A, López-Ortiz G. SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review. Life. 2022;12(2):170.

6. Eaaswarkhanth M, Al Madhoun A, Al-Mulla F. Could the D614G substitution in the SARSCoV- 2 spike (S) protein be associated with higher COVID-19 mortality? Int J Infect Dis. 2020;96:459-460.

7. Elizondo V, Harkins GW, Mabvakure B, Smidt S, Zappile P, Marier C, et al. SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay. Emerg Microbes Infect. 2021;10(1):51-65.

8. Morris CP, Luo CH, Amadi A, Schwartz M, Gallagher N, Ray SC, et al. An Update on SARS-CoV-2 Diversity in the United States National Capital Region: Evolution of Novel and Variants of Concern. Clin Infect Dis. 2021 ciab636. Disponible en: https://doi.org/10.1093/cid/ciab636

9. Courjon J, Contenti J, Demonchy E, Levraut J, Barbry P, Rios G, et al. COVID-19 patients age, comorbidity profiles and clinical presentation related to the SARS-CoV-2 UK-variant spread in the Southeast of France. Sci Rep. 2021;11(1):18456.

10. Stirrup O, Boshier F, Venturini C, Guerra-Assunção JA, Alcolea-Medina A, Beckett A, et al. SARSCoV- 2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study. BMJ Open Respir Res. 2021;8(1):e001029.

11. Zhao S, Lou J, Chong MKC, Cao L, Zheng H, Chen Z, et al. Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2. Viruses. 2021;13(4):638.

12. Nagy Á, Pongor S, Győrffy B. Different mutations in SARS-CoV-2 associate with severe and mild outcome. Int J Antimicrob Agents. 2021 Feb;57(2):106272.

13. Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPHS, et al. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2021:ciab721.

14. Taylor CA, Patel K, Pham H, Whitaker M, Anglin O, Kambhampati AK, et al. Severity of Disease Among Adults Hospitalized with Laboratory- Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January- August 2021. MMWR Morb Mortal Wkly Rep. 2021;70(43):1513-1519.

15. Hoang VT, Colson P, Levasseur A, Delerce J, Lagier JC, Parola P, et al. Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France. Infect Genet Evol. 2021;95:105092.

16. Cele S, Jackson L, Khoury DS, Khan K, Moyo- Gwete T, Tegally H, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2021;1-16.

17. Singhal T. The Emergence of Omicron: Challenging Times Are Here Again! Indian J Pediatr. 2022:1-7.